Renal profile of chronic hepatitis C patients with sofosbuvir-based therapy.
Mohammad El-SayedZeinab AbdellatifAisha ElsharkawyMohamed El KassasReham Abd ElmoniemAmaal MarzoukRabab FouadGamal EsmatShereen Abdel AlemPublished in: Infection (2020)
SOF-based therapies seem to be safe in CHC patients with baseline normal or slightly impaired renal function.